Establishment Labs Announces Participation in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced CEO Juan José Chacón-Quirós and CFO Renee Gaeta will participate in the BTIG Virtual MedTech Conference from February 17-19, 2021. They are scheduled to present at 10:00 am ET on February 19. The conference offers a platform for discussions on the company's focus on women's health, particularly in breast aesthetics with their Motiva Implants®.

A live webcast and archived presentation will be accessible on their investor relations website.

Positive

• Participation in BTIG Virtual MedTech Conference highlights the company's commitment to investor engagement.
• Motiva Implants® have a global presence, available in more than 80 countries.
• Received FDA approval for investigational device exemption for the Motiva Implant® clinical trial.

Negative

• None.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference, which is being held February 17-19, 2021. Mr. Chacón-Quirós and Mrs. Gaeta are scheduled to speak to conference attendees at 10:00 am ET on Friday, February 19, 2021.

A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005068/en/

FAQ

When is the BTIG Virtual MedTech Conference for Establishment Labs Holdings Inc. scheduled?

The BTIG Virtual MedTech Conference is scheduled for February 17-19, 2021.

Who will be presenting for Establishment Labs at the BTIG Conference?

CEO Juan José Chacón-Quirós and CFO Renee Gaeta will be presenting.

Where can I watch the presentation of Establishment Labs at the conference?

The presentation will be available via live webcast on Establishment Labs' investor relations website.

What products does Establishment Labs focus on?

Establishment Labs focuses on women's health, particularly breast aesthetics with their Motiva Implants®.

What is the significance of Motiva Implants® for Establishment Labs?

Motiva Implants® are a key product in establishing the company's presence in the global breast aesthetics market.